Sermorelin 10mg

Sermorelin belongs to a group of growth hormone releasing hormone (GHRH) analogues that have emerged in recent years with the aim of retaining the beneficial effects of natural GHRH while circumventing undesirable outcomes. Sermorelin, also known as Geref, is currently utilized clinically to control growth hormone secretion., but the peptide is of additional interest for its abilities to:

• reduce scarring following heart attack,
• increase bone density,
• improve nutrition in chronic illness,
• improve renal function,
• fight the effects of dementia, and
• reduce seizure activity.

1. Sermorelin and Heart Health

Although heart attacks are acutely life-threatening, they can also result in long-term disability due to various complications such as heart failure, cardiac conduction abnormalities (arrhythmias), reduced exercise capacity, and persistent pain, among others. These issues often arise from cardiac remodeling, a process that occurs in response to damage suffered by myocytes (heart muscle cells). Notably, cardiac remodeling not only causes scarring in the affected area but also extends to the surrounding undamaged regions.

As a consequence, it gives rise to several chronic problems. Research has demonstrated that the prevention of cardiac remodeling can yield significant improvements in both immediate post-heart attack outcomes and long-term prognosis, positively impacting patients in the years that follow.

In 2016, a study in pigs revealed that sermorelin administration is effective in reducing the remodeling that follows a heart attack. The research showed that sermorelin:

• reduces cell death in cardiomyocytes,
• increases the production of extracellular matrix components needed for adequate healing,
• increases the growth of blood vessels to damaged tissue, and
• reduces the production of substances that causes damaging inflammation.

Clinically, sermorelin demonstrates positive effects on various aspects of heart function, including improved diastolic function, reduced scar size, and increased capillary growth[1][2]. Current research is actively investigating the potential benefits of sermorelin in treating other forms of heart disease, such as heart failure and valve disorders.

Furthermore, treatment with growth hormone-releasing hormone (GHRH) has been shown to reduce scar mass. Figure A depicts a graph illustrating the percentage change in scar mass over time and its relationship to the percentage of left ventricular mass. Figure B displays images of the heart before and after 4 weeks of sermorelin treatment or placebo, highlighting the impact of the treatment on scar mass.

2. Sermorelin and Epilepsy

Gamma-aminobutyric acid (GABA) is a signaling molecule within the central nervous system, renowned for its capacity to diminish electrical activity in the spinal cord and overall excitability in the central nervous system. Several anti-seizure medications function either by elevating GABA levels in the central nervous system or by binding to GABA receptors and emulating the effects of GABA.

In a recent study involving mice with epilepsy, researchers administered GHRH analogues, such as sermorelin, to investigate the impact of these peptides on seizure activity. Surprisingly, GHRH analogues demonstrated efficacy in suppressing seizures by activating GABA receptors[3]. This groundbreaking discovery is an active area of research, as current seizure medications, although effective, are associated with various harmful side effects that limit their clinical application.

3. Sermorelin and Sleep

Compelling evidence supports the role of orexin, a potent neurochemical produced by specific neurons in the brain, in the regulation of sleep cycles. Moreover, it is well-established that growth and healing processes, strongly linked to growth hormone secretion, predominantly occur during sleep.

In the case of rainbow trout research, findings suggest that this connection is not coincidental; a functional GHRH axis is crucial for proper orexin secretion and function. Furthermore, the study indicates that the administration of sermorelin and other GHRH agonists from external sources can enhance orexin secretion[4]. As a result, ongoing research is exploring the potential benefits of utilizing sermorelin in addressing sleep disorders.

4. Sermorelin Preferred to Growth Hormone

Sermorelin, a derivative of growth hormone releasing hormone, produces similar effects to GH, such as increasing muscle mass, promoting long bone growth, and reducing adipose tissue. However, unlike GH, sermorelin offers distinct advantages with fewer side effects. It is considered the preferred method for elevating GH levels in humans due to several reasons.

One primary reason for the preference of sermorelin is its susceptibility to physiological feedback mechanisms. These mechanisms help prevent common issues encountered with direct GH administration, including overdose, improper dosing, and unintended side effects like edema, joint pain, and disruptions in normal physiological functions[5].

Another significant advantage of sermorelin is its resistance to tachyphylaxis, a phenomenon where the body becomes tolerant to a medication, necessitating higher doses to achieve desired effects. Unlike some medications, sermorelin does not induce significant tachyphylaxis. Studies involving long-term use of the peptide in both clinical settings and animal research have shown that the body responds uniquely to sermorelin. Instead of down-regulating the production of GHRH receptors, the body increases their production with sermorelin administration. This ensures that the peptide’s effects remain consistent, tachyphylaxis is minimal, and dose escalation is generally unnecessary[6].

Moreover, sermorelin exhibits moderate side effects, has low oral bioavailability, but excellent subcutaneous bioavailability in mice. It is essential to emphasize that sermorelin available for purchase at Peptide Shop is strictly limited to educational and scientific research purposes only, and it is not intended for human consumption. The product should only be obtained by licensed researchers.

[Note: The information regarding sermorelin’s effects and usage is provided for educational purposes only and is not an endorsement or recommendation for its use.]

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Richard F. Walker, Ph.D, R.Ph, lead author of A better approach to management of adult-onset growth hormone insufficiency?”, received a BS in pharmacy from Rutgers University, a MS in Biochemistry from New Mexico State University and a PhD in a physiology from Rutgers University. He holds postdoctoral fellowships in neuroendocrinology and neuropharmacology at Duke University College of Medicine (Center for the Study of Aging and Human Development) and the University of California, Berkeley, respectively.

Richard F. Walker, Ph.D, R.Ph is being referenced as one of the leading scientists involved in the research and development of Sermorelin. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Shop and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Richard F. Walker, Ph.D, R.Ph is listed in [5] under the referenced citations.

1. L. L. Bagno et al., “Growth Hormone–Releasing Hormone Agonists Reduce Myocardial Infarct Scar in Swine With Subacute Ischemic Cardiomyopathy,” J. Am. Heart Assoc. Cardiovasc. Cerebrovasc. Dis., vol. 4, no. 4, Mar. 2015.
2. R. M. Kanashiro-Takeuchi et al., “New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor,” Oncotarget, vol. 6, no. 12, pp. 9728–9739, Mar. 2015.
3. S. Tang et al., “Interactions between GHRH and GABAARs in the brains of patients with epilepsy and in animal models of epilepsy,” Sci. Rep., vol. 7, Dec. 2017.
4. B. S. Shepherd et al., “Endocrine and orexigenic actions of growth hormone secretagogues in rainbow trout (Oncorhynchus mykiss),” Comp. Biochem. Physiol. A. Mol. Integr. Physiol., vol. 146, no. 3, pp. 390–399, Mar. 2007.
5. R. F. Walker, “Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?,” Clin. Interv. Aging, vol. 1, no. 4, pp. 307–308, Dec. 2006.
6. S. T. Wahid, P. Marbach, B. Stolz, M. Miller, R. A. James, and S. G. Ball, “Partial tachyphylaxis to somatostatin (SST) analogues in a patient with acromegaly: the role of SST receptor desensitisation and circulating antibodies to SST analogues,” Eur. J. Endocrinol., vol. 146, no. 3, pp. 295–302, Mar. 2002.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body.  These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.  Bodily introduction of any kind into humans or animals is strictly forbidden by law.